CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the ...
The Phase 2 open-label, multicenter study evaluated safety, tolerability and efficacy of BMB-101 in adults with drug-resistant Absence Seizures and DEE. A total of 24 patients were enrolled, exceeding ...
Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...
Introduction: Despite extensive research on COVID-19 vaccines, comparative data on the long-term humoral response across multiple vaccine platforms and heterologous regimens remain limited. SARS-CoV-2 ...
Abstract: The following three factors restrict the application of existing low-light image enhancement methods: corruptions induced by the light-up process, color distortion, and a restricted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results